Business Description
Inovio Pharmaceuticals Inc
NAICS : 325414
SIC : 2834
ISIN : US45773H2013
Total Employee Number:
112Description
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.58 | |||||
Equity-to-Asset | 0.09 | |||||
Debt-to-Equity | 1.83 | |||||
Debt-to-EBITDA | -0.1 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -87.5 | |||||
3-Year EBITDA Growth Rate | 49.6 | |||||
3-Year EPS without NRI Growth Rate | 48.7 | |||||
3-Year FCF Growth Rate | 44.2 | |||||
3-Year Book Growth Rate | -67.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 59.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 1198.93 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.28 | |||||
9-Day RSI | 53.58 | |||||
14-Day RSI | 54.52 | |||||
3-1 Month Momentum % | 2.32 | |||||
6-1 Month Momentum % | -32.74 | |||||
12-1 Month Momentum % | -46.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -48.4 | |||||
Shareholder Yield % | -27.55 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -118021.92 | |||||
OCF Margin % | -117735.57 | |||||
ROE % | -609.14 | |||||
ROA % | -108.37 | |||||
ROIC % | -155.12 | |||||
3-Year ROIIC % | 14888.96 | |||||
ROC (Joel Greenblatt) % | -912.53 | |||||
ROCE % | -467.31 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1238.5 | |||||
PB Ratio | 23.36 | |||||
Price-to-Tangible-Book | 26.93 | |||||
EV-to-EBIT | -1.21 | |||||
EV-to-EBITDA | -1.27 | |||||
EV-to-Revenue | 1549.3 | |||||
EV-to-Forward-Revenue | 1.24 | |||||
EV-to-FCF | -1.25 | |||||
Price-to-GF-Value | 5.98 | |||||
Earnings Yield (Greenblatt) % | -81.86 | |||||
FCF Yield % | -62.28 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Inovio Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.058 | ||
| EPS (TTM) (€) | -1.006 | ||
| Beta | 2.0636 | ||
| 3-Year Sharpe Ratio | -0.05 | ||
| 3-Year Sortino Ratio | -0.09 | ||
| Volatility % | 119.51 | ||
| 14-Day RSI | 54.52 | ||
| 14-Day ATR (€) | 0.04932 | ||
| 20-Day SMA (€) | 1.08865 | ||
| 12-1 Month Momentum % | -46.79 | ||
| 52-Week Range (€) | 0.557 - 2.28 | ||
| Shares Outstanding (Mil) | 103.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Inovio Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Inovio Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-03-12 16:30 | In 173 days | ||
| Annual report for 2026 | 2027-03-12 | In 172 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-12 | In 172 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-10 16:30 | In 51 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 50 days | ||
| H.C. Wainwright 28th Annual Global Investment Conference | 2026-09-11 07:00 | 1.13 (+0.00%) | ||
| Cantor Global Healthcare Conference | 2026-09-09 15:20 | 1.22 (+0.00%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 16:30 | 0.69 (+11.29%) | ||
| Second quarter earnings results for 2026 | 2026-08-12 | 0.69 (+11.29%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 08:45 | 1.02 (+0.00%) |
Show
Entries
Inovio Pharmaceuticals Inc Frequently Asked Questions
What is Inovio Pharmaceuticals Inc(FRA:GBM)'s stock price today?
The current price of FRA:GBM is €1.08. The 52 week high of FRA:GBM is €2.28 and 52 week low is €0.56.
When is next earnings date of Inovio Pharmaceuticals Inc(FRA:GBM)?
The next earnings date of Inovio Pharmaceuticals Inc(FRA:GBM) is 2026-11-10 Est..
Does Inovio Pharmaceuticals Inc(FRA:GBM) pay dividends? If so, how much?
Inovio Pharmaceuticals Inc(FRA:GBM) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers